In agreement with this result, pirfenidone was explained to disrupt tumor–stromal interactions by inhibiting the effect of platelet-derived growth factor (PDGF-A), hepatocyte growth factor (HGF), collagen type I, and fibronectin which all play an important role in tumor–stromal interactions [20]. The gene discussed is FN1; the disease is neoplasm.